Rett Syndrome

LIke ThisLIke ThisLIke ThisLIke ThisLIke This

Brief description:

The current project aims to learn more about the development of Rett Syndrome–a genetic disorder found only in girls—and how the disorder responds to treatment with new drugs. We will be measuring brain activity in girls with Rett Syndrome who are enrolled in a clinical trial at Boston Children’s Hospital, both before and after they receive the drug. In this way, we aim to see whether the drugs are having positive effects and also to identify a reliable biological marker to determine the severity of the disorder.

 To properly investigate neural functioning in girls with Rett Syndrome, we are also recruiting typically developing girls to provide comparison data.  Children in the control group will not receive any medication.

 Eligibility for Study Participation:

  • Girls 2 to 12 years that are typically developing, with no history of pre or postnatal difficulties, and who have normal, uncorrected, vision

Participation Details:

If you decide to participate in this study, which has a longitudinal design, it will involve an initial visit to the lab, and a follow up visit twenty weeks later. Each visit will last about 1 ½ hours and will be scheduled at a time that is convenient for you and your child. Parents will be with their child at all times.

Research Contact:

Full Description:

Rett Syndrome (RTT) is a genetic disorder caused by a single mutation on the X-chromosome. RTT is characterized by toddlerhood regression of motor and language milestones, as well as onset of stereotypies, breathing abnormalities and gastrointestinal complications.

Currently, methods for measuring neural function in girls with Rett Syndrome do not exist, but they are urgently needed so that researchers can learn more about how to treat this neurodevelopmental disorder. One potential pathway toward assessing neural function is through the visual system. We know a great deal about how this system functions in the brain, and can therefore draw conclusions about other neural networks based on how the visual system performs. This has been shown in previous work done in mouse models of RTT, which used assessments of the visual system in order gain information about functional levels in related neural networks. Researchers have also identified a drug that helps RTT mice develop with normal brain functioning. This drug is now being tested in a human clinical trial at Boston Children’s Hospital, and our goal is to build on the mouse model research in order to determine the effects of the drug in human use.  We will be using EEG to measure neural function in response to visual stimuli, both before and after treatment. In addition to assessing the effectiveness of this new drug, our goal is to identify a reliable biological marker that can be used for earlier identification and improved assessment of clinical interventions. 

Request an Appointment

If this is a medical emergency, please dial 9-1-1. This form should not be used in an emergency.

Patient Information
Date of Birth:
Contact Information
Appointment Details
Send RequestIf you do not see the specialty you are looking for, please call us at: 617-355-6000.International visitors should call International Health Services at +1-617-355-5209.
Please complete all required fields

This department is currently not accepting appointment requests online. Please call us at: 617-355-6000. International +1-617-355-6000.

This department is currently not accepting appointment requests online. Please call us at: 617-355-6000. International +1-617-355-6000.

Thank you.

Your request has been successfully submitted

You will be contacted within 1 business day.

If you have questions or would like more information, please call:

617-355-6000 +1-617-355-6000
Find a Doctor
Search by Clinician's Last Name or Specialty:
Select by Location:
Search by First Letter of Clinician's Last Name: *ABCDEFGHIJKLMNOPQRSTUVWXYZ
Condition & Treatments
Search for a Condition or Treatment:
View allSearch
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”
- Sandra L. Fenwick, President and CEO